Table 1 Characteristics of the included studies
Author | Year | Country | design | Accrual | Histology | FU | Mutation detection | Survival outcomes | Participants (M/W) | Tumor grade (Low/High) | Tumor stage (Ta-1/T2-4) | Age (Median; range) | Gender (male%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rachakonda | 2013 | Germany | prospective | 1995–2010 | BC | 15y | PCR Sanger | OS | 186/93 | 118/209 | 219/108 | 72.8(65.4–79.4)a | NR |
Nakanishi | 1999 | Japan | retrospective | 1970–1995 | UTUC | 300 m | In situ hybridization | DFS | 42/80 | 77/51 | NR | 66(34–84) | 71.9 |
OS | 44/84 | ||||||||||||
Yang CH | 2008 | China | retrospective | 1995–2010 | UC | 10y | streptavidin–biotin method | RFS | 50/44 | 13/81 | NR | 67(21–83) | 41.5 |
Sumit | 2017 | America | retrospective | NR | UC | 200 m | MSK-IMPACT | OS | 266/122 | 35/353 | 38/84 | 66(58–74) | NR |
DSS | 266/122 | ||||||||||||
MFS | 198/91 | ||||||||||||
Song Wu | 2013 | China | retrospective | NR | BC | 120 m | Sanger | OS | 120/96 | NR | 56/64 | NR | NR |
Ismail | 2015 | Germany | prospective | 1995–2010 | BC | 10y | PCR Sanger | OS | 102/79 | 87/127 | 148/66 | 72.8(65.4–79.4)a | NR |
Jenny | 2019 | Germany | retrospective | 2012–2018 | BC | 1600d | PCR | OS | 63/12 | 25/50 | 50/25 | 75(49–97) | 78.7 |
DSS | 63/12 | ||||||||||||
RFS | 63/12 | ||||||||||||
Ivan | 2021 | America | retrospective | 2014–2020 | UC | 6y | NR | OS | 47/31 | NR | NR | 71(66–76) | 62.8 |
Neal | 2023 | America | retrospective | 2014–2021 | UC | 7y | NR | PFS | 64/49 | NR | NR | 67(35–85) | 76% |
OS | 64/49 |